Susquehanna International Group, LLP Enlivex Therapeutics Ltd. Put Options Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
Put Options
3 transactions
Others Institutions Holding ENLV
# of Institutions
25Shares Held
2.57MCall Options Held
79.1KPut Options Held
0-
Armistice Capital, LLC New York, NY1.41MShares$2.22 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny612KShares$961,1540.0% of portfolio
-
Morgan Stanley New York, NY219KShares$344,0630.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny168KShares$264,3750.0% of portfolio
-
Jane Street Group, LLC New York, NY61.1KShares$95,8510.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $28.9M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...